MGC-803 / MGC-803-luc Orthotopic Mouse Model Service for Gastric Cancer

The MGC-803 / MGC-803-luc orthotopic mouse model for gastric cancer enables human tumor cells to colonize the stomach wall of immunodeficient mice, where they establish invasive primary tumors that can be followed over time without invasive procedures. Specializing exclusively in preclinical oncology research, Alfa Cytology supports this model end to end: luciferase-labeled cell preparation, microsurgical implantation into the gastric wall, scheduled in vivo bioluminescence imaging, and full endpoint histopathology.

Overview of MGC-803 / MGC-803-luc Orthotopic Mouse Model for Gastric Cancer

MGC-803 is a human gastric cancer cell line originally reported in 1980 after isolation from the poorly differentiated mucinous adenocarcinoma of a 53-year-old male patient. The line grows as an adherent, epithelial-like monolayer with a population doubling time of roughly 22 hours, carries a chromosome count in the 58–61 range, and displays vigorous tumorigenicity when introduced into immunocompromised animals. Researchers should be aware that STR-based authentication analyses have since flagged MGC-803 as a suspected hybrid lineage sharing genetic material with HeLa, a caveat that informed study design should acknowledge; in practice, the line remains one of the most frequently employed tools in gastric cancer research, particularly within the Asian research community, and reproducible behavior has been documented across a wide range of in vitro and in vivo applications.

Fig 1. Bioluminescence imaging of an MGC803-Luc orthotopic gastric cancer model established by implantation of luciferase-positive tumor fragments onto the gastric serosa, enabling evaluation of primary tumor burden and metastatic dissemination. (Guan, Xiaoqing, et al., 2024)

In orthotopic xenograft work, MGC-803 cells labeled with firefly luciferase (MGC-803-luc) are inoculated beneath the serosa of the mouse stomach, most often in immunodeficient strains such as BALB/c nude or NOD-SCID mice. The resulting primary tumor expands locally and progressively breaches the muscular layers of the gastric wall, a process that luciferase tagging renders visible through repeated whole-animal imaging after D-luciferin administration. Because the bioluminescent signal scales with viable tumor mass, the MGC-803-luc orthotopic model supports quantitative tracking of tumor growth kinetics, treatment-induced regression or regrowth, and the onset of abdominal spread, making it a practical platform for evaluating antitumor and anti-invasive candidate agents. Figure 1 provides a visual summary of how this orthotopic system is assembled and monitored.

Cell Line Information: MGC-803 / MGC-803-luc

MGC-803 has served as a gastric adenocarcinoma research tool for more than four decades, and its luciferase-tagged counterpart extends the same biology into longitudinal imaging studies. The principal characteristics are compiled below.

Our Services

Every MGC-803 / MGC-803-luc engagement at Alfa Cytology is anchored by verified cell banks, sterile microsurgical technique, calibrated IVIS imaging, and a pathology-supported endpoint package, so clients receive a coherent dataset rather than disconnected data fragments.

Workflow of MGC-803 / MGC-803-luc Orthotopic Mouse Model Construction

Establishing an MGC-803 or MGC-803-luc orthotopic gastric tumor is a staged process that moves from authenticated cell material through subserosal inoculation and serial imaging to structured endpoint analysis. The stages below describe the standard execution path used for this platform.

1. Cell Bank Verification and Expansion: MGC-803 or MGC-803-luc stocks are authenticated in-house by STR profiling and confirmed mycoplasma-free, then expanded in vitro under the appropriate serum-supplemented medium.
2. Luciferase Performance Check (MGC-803-luc Only): For luciferase-tagged stocks, signal output per cell is calibrated so that downstream in vivo photon flux can be converted into relative tumor burden.
3. Mouse Conditioning and Randomization: Immunodeficient recipients, typically BALB/c nude or NOD-SCID mice, are acclimatized and distributed into groups by body weight, with anesthesia and analgesia administered per approved protocols.
4. Gastric Wall Exposure: Through a small midline laparotomy performed under aseptic conditions, the stomach is gently externalized and the serosal surface is prepared for cell delivery.
5. Subserosal Cell Inoculation: A single-cell suspension of MGC-803 or MGC-803-luc cells (commonly around 10⁶ cells in a low-volume carrier) is deposited slowly into the subserosal plane of the gastric wall, where the cells anchor and proliferate.
6. Closure and Postoperative Recovery: The abdominal layers are sutured and animals are returned to warmed cages, with daily health and body weight checks until complete recovery.
7. Serial Bioluminescence Monitoring: Following intraperitoneal D-luciferin injection, whole-animal imaging sessions are scheduled at defined intervals to chart primary tumor expansion and detect abdominal dissemination in real time.
8. Endpoint Necropsy and Histology: At the scheduled sacrifice point, the primary gastric tumor is resected and weighed, the stomach is processed for H&E and immunohistochemical assessment of invasion depth, and abdominal organs are surveyed for metastatic foci.

Fig 2. MGC-803 / MGC-803-luc orthotopic mouse model construction workflow.

Case Study-MGC-803 / MGC-803-luc Orthotopic Mouse Model Development

Alfa Cytology has executed preclinical studies on the MGC-803 / MGC-803-luc orthotopic platform for clients investigating gastric cancer growth control and invasion restraint, generating longitudinal bioluminescence records, primary tumor measurements, invasion-depth histology, and abdominal metastasis surveys. Because each engagement is configured around the client’s own therapeutic candidate, study outlines and representative datasets are provided upon request.

Why Choose Alfa Cytology?

The MGC-803 / MGC-803-luc orthotopic platform rewards careful execution: a mislabeled cell bank or an imprecise subserosal injection can compromise an entire study. Alfa Cytology’s operating discipline keeps these risks in check while delivering imaging-rich, decision-ready preclinical data.

• In-house STR and mycoplasma verification applied to every cell bank before expansion.
• Practiced gastric subserosal implantation technique that protects engraftment consistency across cohorts.
• On-site IVIS bioluminescence capability for scheduled, quantitative in vivo tumor monitoring.
• Endpoint pathology with invasion-depth scoring and organ-by-organ metastasis documentation.
• Study configurations spanning antitumor, anti-invasive, and tumor microenvironment readouts.
• Single accountable project team from model design through final data package delivery.

Contact Us

Whether the target is primary tumor control, gastric wall invasion, or abdominal dissemination, Alfa Cytology can configure an MGC-803 / MGC-803-luc orthotopic study around your molecule’s mechanism of action. Contact us today for a feasibility discussion and tailored quotation, or reach out to our scientific team to map out your preclinical study timeline.

For research use only. Not intended for any clinical use.